###begin article-title 0
###xml 28 33 28 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRNP </italic>
Lack of association between PRNP 1368 polymorphism and Alzheimer's disease or vascular dementia
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 41 45 41 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRNP</italic>
###xml 294 299 294 299 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRNP </italic>
###xml 472 477 472 477 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRNP </italic>
###xml 513 518 513 518 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRNP </italic>
###xml 606 611 606 611 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRNP </italic>
Polymorphisms of the prion protein gene (PRNP) at codons 129 and 219 play an important role in the susceptibility to Creutzfeldt-Jakob disease (CJD), and might be associated with other neurodegenerative disorders. Several recent reports indicate that polymorphisms outside the coding region of PRNP modulate the expression of prion protein and are associated with sporadic CJD, although other studies failed to show an association. These reports involved the polymorphism PRNP 1368 which is located upstream from PRNP exon 1. In a case-controlled protocol, we assessed the possible association between the PRNP 1368 polymorphism and either Alzheimer's disease (AD) or vascular dementia (VaD).
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 27 32 27 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRNP </italic>
###xml 190 195 190 195 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRNP </italic>
###xml 223 231 <span type="species:ncbi:9606">patients</span>
###xml 244 252 <span type="species:ncbi:9606">patients</span>
To investigate whether the PRNP 1368 polymorphism is associated with the occurrence of AD or VaD in the Korean population, we compared the genotype, allele, and haplotype frequencies of the PRNP 1368 polymorphism in 152 AD patients and 192 VaD patients with frequencies in 268 healthy Koreans.
###end p 5
###begin title 6
Results and conclusion
###end title 6
###begin p 7
###xml 73 78 73 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRNP </italic>
###xml 230 235 230 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRNP </italic>
###xml 503 508 503 508 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRNP </italic>
###xml 272 280 <span type="species:ncbi:9606">patients</span>
###xml 401 409 <span type="species:ncbi:9606">patients</span>
Significant differences in genotype, allele and haplotype frequencies of PRNP 1368 polymorphism were not observed between AD and normal controls. There were no significant differences in the genotype and allele frequencies of the PRNP 1368 polymorphism between Korean VaD patients and normal controls. However, in the haplotype analysis, haplotype Ht5 was significantly over-represented in Korean VaD patients. This was the first genetic association study of a polymorphism outside the coding region of PRNP in relation to AD and VaD.
###end p 7
###begin title 8
Background
###end title 8
###begin p 9
###xml 911 914 911 914 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APP</italic>
###xml 936 939 936 939 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PS1</italic>
###xml 961 964 961 964 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PS2</italic>
###xml 998 1002 998 1002 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ApoE</italic>
###xml 1005 1006 1005 1006 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 1354 1357 1348 1351 <sup xmlns:xlink="http://www.w3.org/1999/xlink">res</sup>
###xml 1479 1481 1470 1472 <sup xmlns:xlink="http://www.w3.org/1999/xlink">C </sup>
###xml 1491 1492 1482 1483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 1493 1494 1484 1485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 1599 1601 1587 1589 <sup xmlns:xlink="http://www.w3.org/1999/xlink">C </sup>
###xml 1602 1603 1590 1591 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
Alzheimer's disease (AD), the most common cause of dementia in the aged population, is associated with progressive memory deterioration and disordered cognitive function resulting from a loss of cholinergic transmission and characterized neuropathologically by the presence of neurofibrillary tangles and amyloid plaques in the brain and clinically by gradual loss of memory. These changes may result from destructive processes involving the disruption of microtubule assembly and synaptic loss. Further neuronal damage and disease progression are consequences of this damage. Although the processes involved in AD could be triggered by many environmental factors, genetic studies have shown that in some cases mutations and polymorphisms of particular genes can confer susceptibility to the degenerative process. Several genes associated with AD have been identified, including amyloid precursor protein gene (APP), presenilin-1 gene (PS1), presenilin-2 gene (PS2), and the apolipoprotein E gene (ApoE) [1]. AD and prion diseases, such as Creutzfeldt-Jakob disease (CJD), share a number of clinical, pathogenetic and pathological features. A structural hallmark of AD is amyloid-beta peptide (Abeta) aggregates in extracellular amyloid deposits defined as senile plaques, while in CJD there is an accumulation of abnormal protease-resistant isoform (PrPres) in neurons and in extracellular amyloid-like aggregates. Abeta-positive senile plaques in AD brains commonly contain PrPC deposits [2-4] and incidental Abeta-positive senile plaques in prion diseases such as CJD may also be positive for PrPC [5].
###end p 9
###begin p 10
Vascular dementia (VaD) is the second most common cause of dementia after AD. VaD is a clinical syndrome causing cognitive decline due to cerebrovascular lesions. Risk factors for VaD are age, sex, race, hypertension, smoking, diabetes mellitus, and hypercholesterolemia. However, there is no conclusive evidence for the association of genetic polymorphisms with VaD. VaD and prion diseases share some pathophysiological similarities, such as the occurrence of dementia.
###end p 10
###begin p 11
###xml 70 74 70 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRNP</italic>
###xml 118 123 118 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRNP </italic>
###xml 313 314 313 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 315 316 315 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 357 362 357 362 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRNP </italic>
###xml 406 407 406 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 408 410 408 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 473 478 473 478 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRNP </italic>
###xml 522 524 522 524 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 525 527 525 527 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 651 653 651 653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 654 656 654 656 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 712 717 712 717 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRNP </italic>
###xml 767 769 767 769 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 800 805 800 805 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRNP </italic>
###xml 829 834 829 834 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRNP </italic>
###xml 921 923 921 923 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 924 926 924 926 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 996 998 996 998 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 999 1001 999 1001 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 1134 1139 1134 1139 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRNP </italic>
###xml 1204 1206 1204 1206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 1218 1223 1218 1223 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRNP </italic>
###xml 1341 1346 1341 1346 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRNP </italic>
###xml 110 116 <span type="species:ncbi:9606">humans</span>
###xml 1283 1291 <span type="species:ncbi:9606">patients</span>
Prion protein contains 253 amino acids encoded by prion protein gene (PRNP), located on chromosome 20p12.3 in humans. PRNP plays an important role in conferring susceptibility or resistance to prion disease. A number of mutations in the open reading frame (ORF) are linked to the familial form of prion diseases [6,7]. Polymorphisms at codons 129 or 219 of PRNP are susceptibility factors to sporadic CJD [8-11]. In several European populations, an association between the PRNP codon 129 polymorphism and AD was reported [12-15]. In contrast to these studies, other studies failed to detect a significant association between this polymorphism and AD [16-18], and in Asian populations, no association between the PRNP codons 129/219 polymorphisms and AD was reported [19]. Recently, the polymorphism (PRNP 1368) in an upstream of PRNP exon 1 was found to be associated with sporadic CJD in British and German populations [20,21], but this association was not seen in Dutch and Korean populations [22,23]. This polymorphism was studied in other diseases in addition to sporadic CJD. In a British population, there was no association of PRNP 1368 polymorphism with frontotemporal lobar degeneration (FTLD) [24]. Although PRNP 1368 polymorphism has been studied in sporadic CJD and FTLD patients, a case-controlled association study between the PRNP 1368 polymorphism and either AD or VaD has not been reported thus far.
###end p 11
###begin p 12
###xml 134 139 134 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRNP </italic>
###xml 160 168 <span type="species:ncbi:9606">patients</span>
In the present study, the purpose was to investigate the genotype and allele frequency of a polymorphism outside the coding region of PRNP in Korean AD and VaD patients and to determine the correlation between this polymorphism and the incidence of AD and VaD in the Korean population.
###end p 12
###begin title 13
Methods
###end title 13
###begin title 14
Subjects
###end title 14
###begin p 15
###xml 311 313 309 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 1086 1088 1082 1084 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 1254 1256 1250 1252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 1764 1765 1758 1759 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 29 37 <span type="species:ncbi:9606">patients</span>
###xml 452 460 <span type="species:ncbi:9606">patients</span>
###xml 499 507 <span type="species:ncbi:9606">patients</span>
###xml 828 836 <span type="species:ncbi:9606">patients</span>
###xml 899 907 <span type="species:ncbi:9606">patients</span>
###xml 1369 1377 <span type="species:ncbi:9606">patients</span>
###xml 1537 1545 <span type="species:ncbi:9606">patients</span>
###xml 1731 1739 <span type="species:ncbi:9606">patients</span>
###xml 1748 1756 <span type="species:ncbi:9606">patients</span>
Analysis included 152 Korean patients with AD (51 male and 101 female; mean age at disease onset 73.48 +/- 8.00 years), which were diagnosed according to the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria [25] with minor modification specifying the gradual onset and progression of memory loss with a duration of at least 12 months. None of these patients reported family history of AD. All AD patients were gathered from Chunchon, South Korea and were examined in the Department of Neurology, Chunchon Sacred Heart Hospital. General medical and neurological examinations, neuropsychological testing, and computed topography scans were performed to exclude other forms of dementia. Blood samples were collected from 152 AD patients between May 2000 and June 2005. One hundred ninety two Korean patients with VaD (100 male and 92 female; mean age: 71.95 +/- 8.92 years) were diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) [26] and National Institute of Neurological Disorders and Stroke-Association Internationale pour la Recherche et l'Enseignement en Neurosciences (NINDS-AIREN) criteria [27] after clinical examination and neuropsychological testing, including mini-mental state examination (MMSE). VaD patients were gathered from Anyang, South Korea and were examined in the Department of Neurology, Hallym University Hospital. Blood samples were collected from 192 VaD patients between May 2000 and June 2008. The control subjects were 268 unrelated individuals (118 male and 150 female; mean age 71.17 +/- 8.68 years) matched for age and ethnic background to AD patients and VaD patients (Table 1). All control subjects were volunteers recruited from routine health checkups at the Chunchon Sacred Heart Hospital. None of them presented symptoms of dementia or any movement disorders. Absence of dementia was determined by considering past history and Korean MMSE criterion (score of >24). Blood samples were collected from 268 healthy Korean volunteers between May 2000 and June 2005. The study was approved by the Ethical Committee of Chunchon Sacred Heart Hospital and an informed consent was given by all subjects or their caregivers. All blood samples were frozen at -70degreesC prior to analysis.
###end p 15
###begin p 16
###xml 30 38 <span type="species:ncbi:9606">patients</span>
Characteristics of AD and VaD patients and controls
###end p 16
###begin p 17
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 56 64 <span type="species:ncbi:9606">patients</span>
aBased on the difference between controls and AD or VaD patients
###end p 17
###begin title 18
Genotyping
###end title 18
###begin p 19
###xml 333 338 332 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRNP </italic>
###xml 412 416 410 414 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Taq </italic>
###xml 450 451 448 449 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 500 504 498 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Taq </italic>
###xml 1024 1031 985 992 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pvu II </italic>
###xml 1361 1365 1322 1326 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Taq </italic>
Genomic DNA was extracted from 200 mul blood using the QIAamp DNA blood mini kit (Qiagen, USA) following the supplier's instructions. Polymerase chain reaction (PCR) was performed with J-1 (GAGAAAACCTTGCGTCAGCA) and J-2 (AAGGTGCAGAAAAGATGGGC) primers. These primers were designed to amplify a 586 bp product in an upstream region of PRNP exon 1. The PCR reagents contained 50 pmole of each primer, 5 mul of 10 x Taq DNA polymerase buffer, 1.5 mM MgCl2, 0.2 mM of each dNTP mixtures, and 2.5 units of Taq DNA polymerase (Promega, USA). The PCR conditions were 94degreesC for 2 min to denature, and 35 cycles of 94degreesC for 45 sec, 56degreesC for 45 sec, and 72degreesC for 1 min 30 sec, and then 1 cycle of 72degreesC for 10 min to extend the reaction. The Perkin-Elmer Cetus DNA thermal cycler (Pekin-Elmer, USA) was used. Restriction cleavage sites were searched using Webcutter, ver. 2.0 (Carolina Biological Supply Co., USA). A 20 mul aliquot of purified PCR mixture was digested at 37degreesC for 1 h with 5 units of Pvu II (Invitrogen, USA). Restriction products were separated on a 1.5% agarose gel and visualized with ethidium bromide staining under UV light. The purification of PCR products for sequencing was done using a QIAquick gel extraction kit (Qiagen, USA). The PCR products were directly sequenced on an ABI 377 automatic sequencer using a Taq dideoxy terminator cycle sequencing kit (ABI, USA) and the same primers as indicated earlier in the standard conditions.
###end p 19
###begin title 20
Statistical analyses
###end title 20
###begin p 21
###xml 5 7 3 5 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 46 51 44 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRNP </italic>
###xml 190 191 188 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 353 354 351 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 393 395 389 391 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 498 500 494 496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 612 620 <span type="species:ncbi:9606">patients</span>
A chi2 test was used to determine whether the PRNP 1368 polymorphism was in Hardy-Weinberg equilibrium (HWE) in the Korean population. Odds ratios (OR) with 95% confidence interval (CI) and P-values were calculated by using the codominant model, controlling for age and sex as covariates. Differences in age of populations were analyzed using Student's t-test, and sex differences by using chi2 test. Haplotypes and their frequencies were inferred using the algorithm developed by Stephens et al. [28]. Fisher's exact test was used to analyze differences in haplotype frequency between the normal population and patients with AD and VaD. The statistical powers were calculated using Statistical Power Calculator .
###end p 21
###begin title 22
Results
###end title 22
###begin p 23
###xml 28 33 28 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRNP </italic>
###xml 75 77 75 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 100 102 100 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 196 201 196 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRNP </italic>
###xml 495 500 495 500 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRNP </italic>
###xml 525 526 525 526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 559 564 559 564 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRNP </italic>
###xml 342 350 <span type="species:ncbi:9606">patients</span>
###xml 424 432 <span type="species:ncbi:9606">patients</span>
The genotype frequencies at PRNP 1368 were in HWE in Korean control group (P = 0.742) and AD group (P = 0.226), not in VaD group (P = 0.025) (data not shown). To examine a correlation between the PRNP 1368 polymorphism and susceptibility of AD in Koreans, we examined the genotype and allele frequencies of this polymorphism in 152 Korean AD patients and in 268 healthy controls. No significant difference between Korean AD patients and controls was found in genotype or allele frequency of the PRNP 1368 polymorphism (Table 2). This result suggests that the PRNP 1368 polymorphism does not increase susceptibility to AD. When our data set was stratified by gender, there was no significant association between this polymorphism and AD (data not shown).
###end p 23
###begin p 24
###xml 91 99 <span type="species:ncbi:9606">patients</span>
###xml 109 117 <span type="species:ncbi:9606">patients</span>
Genotype and allele frequencies of the PRNP 1368 polymorphism in the normal population, AD patients, and VaD patients
###end p 24
###begin p 25
Figures in parentheses are percentages
###end p 25
###begin p 26
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
aOdds ratio
###end p 26
###begin p 27
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
bConfidence interval
###end p 27
###begin p 28
###xml 60 65 60 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRNP </italic>
###xml 271 272 271 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 405 410 405 410 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRNP </italic>
###xml 553 554 553 554 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 88 96 <span type="species:ncbi:9606">patients</span>
###xml 242 250 <span type="species:ncbi:9606">patients</span>
###xml 344 352 <span type="species:ncbi:9606">patients</span>
###xml 358 366 <span type="species:ncbi:9606">patients</span>
###xml 537 545 <span type="species:ncbi:9606">patients</span>
We also investigated the genotype and allele frequencies of PRNP 1368 in 192 Korean VaD patients to determine whether this polymorphism correlated with VaD. There were no significant differences in genotype and allele frequencies between VaD patients and controls (Table 2). In addition, analysis of the haplotype frequency was performed in AD patients, VaD patients and controls. Six haplotypes of the 3 PRNP polymorphisms were constructed in Koreans. One (ht 5) of these six haplotypes was significantly over-represented in Korean VaD patients (Table 3).
###end p 28
###begin p 29
###xml 77 85 <span type="species:ncbi:9606">patients</span>
###xml 95 103 <span type="species:ncbi:9606">patients</span>
Haplotype frequency of three PRNP polymorphisms in the normal population, AD patients, and VaD patients
###end p 29
###begin title 30
Discussion
###end title 30
###begin p 31
###xml 73 78 73 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRNP </italic>
In this study, we failed to detect a significant association between the PRNP 1368 polymorphism and the occurrence of either AD or VaD in the Korean population.
###end p 31
###begin p 32
###xml 34 39 34 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRNP </italic>
###xml 116 117 116 117 <sup xmlns:xlink="http://www.w3.org/1999/xlink">C</sup>
###xml 430 435 430 435 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRNP </italic>
###xml 534 539 534 539 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRNP </italic>
###xml 644 645 644 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 677 682 677 682 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRNP </italic>
###xml 781 786 781 786 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRNP </italic>
###xml 894 899 894 899 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRNP </italic>
###xml 231 239 <span type="species:ncbi:9606">patients</span>
###xml 707 715 <span type="species:ncbi:9606">patients</span>
There is the possibility that the PRNP 1368 polymorphism is not functional with regard to affecting the level of PrPC. Another possibility is that a false negative result was obtained due to statistical powers. Data for AD and VaD patients showed a statistical power of 19.1% and 11.2%, respectively, at the Type I error rate of 0.05 compared with healthy controls. The statistical powers aren't high enough for ensuring that the PRNP 1368 polymorphism is not relevant to prion replication. However, in the haplotype analysis among 3 PRNP polymorphisms, haplotype ht5 was the only haplotype significantly associated with VaD (p = 0.013) (Table 3) and the genotype frequency of PRNP 1368 polymorphism in VaD patients was not in HWE. These results suggested some interaction among 3 PRNP polymorphisms in the determination of VaD risk and were needed for further evaluation of the association of PRNP 1368 polymorphism with VaD in other ethnic groups.
###end p 32
###begin p 33
###xml 239 244 239 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRNP </italic>
###xml 367 372 367 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRNP </italic>
###xml 448 450 448 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 451 453 451 453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 582 587 582 587 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRNP </italic>
###xml 630 632 630 632 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 755 760 755 760 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRNP </italic>
###xml 844 846 844 846 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 847 849 847 849 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
Although the exact function of the prion protein is not fully understood, it might be involved in the development and intensity of oxidative stress and, thereby, contribute to neurodegeneration. Thus, polymorphisms in the coding region of PRNP might influence other neurodegenerative disorders in addition to prion diseases. Many studies on a correlation between the PRNP codon 129 and AD in various populations have yielded contradictory results [12-19]. This controversial result may be due to the different sample size of the population analyzed, to a difference in frequency of PRNP genotypes between different ethnic groups [29], or even to a difference in age of onset. In our previous studies, we failed to detect a significant association between PRNP polymorphism at codons 129/219 and the risk for AD or VaD in the Korean population [30,31].
###end p 33
###begin p 34
###xml 88 92 88 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRNP</italic>
###xml 130 135 130 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRNP </italic>
###xml 235 240 235 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRNP </italic>
###xml 342 344 342 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 345 347 345 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 356 361 356 361 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRNP </italic>
###xml 398 403 398 403 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRNP </italic>
###xml 426 428 426 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 449 454 449 454 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRNP </italic>
###xml 519 524 519 524 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRNP </italic>
###xml 587 589 587 589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 590 592 590 592 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 642 647 642 647 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRNP </italic>
###xml 721 726 721 726 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRNP </italic>
###xml 762 767 762 767 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRNP </italic>
###xml 932 936 932 936 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRNP</italic>
###xml 997 1002 997 1002 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRNP </italic>
###xml 1041 1046 1041 1046 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRNP </italic>
###xml 1106 1108 1106 1108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 1173 1175 1173 1175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1176 1178 1176 1178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 325 331 <span type="species:ncbi:9913">cattle</span>
###xml 336 340 <span type="species:ncbi:10090">mice</span>
###xml 457 472 <span type="species:ncbi:10090">transgenic mice</span>
###xml 533 537 <span type="species:ncbi:10090">mice</span>
###xml 926 931 <span type="species:ncbi:9606">human</span>
Recently, there has been growing concern about several polymorphisms outside the ORF of PRNP, as there is evidence that levels of PRNP expression influence incubation time and the susceptibility to prion diseases. Polymorphisms in the PRNP promoter region may be associated with increased susceptibility of prion diseases in cattle and mice [32-34]. These PRNP promoter polymorphisms influence the PRNP gene expression level [35]. Overexpression of PRNP in transgenic mice led to a decrease in incubation time, whereas PRNP knockout mice were resistant to prion disease after infection [36,37]. Therefore, we suggest that the polymorphism of PRNP 1368, located in the promoter region, may influence the expression of the PRNP gene; the promoter polymorphisms of PRNP might also be associated with other neurodegenerative diseases. In previous studies, several polymorphisms were identified in intronic and upstream regions of human PRNP. The single nucleotide polymorphism (SNP) at position -101 (PRNP 12533) within the regulatory region of PRNP was associated with sporadic CJD in the British population [38], but not in samples derived from Dutch and German populations [20,39].
###end p 34
###begin p 35
###xml 62 67 62 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRNP </italic>
###xml 154 159 154 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRNP </italic>
###xml 211 216 211 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRNP </italic>
Even though these results did not show a relationship between PRNP 1368 and AD or VaD, it would be useful to assess associations between AD/VaD and other PRNP polymorphisms in the promoter region, including the PRNP 12533 polymorphism.
###end p 35
###begin title 36
Conclusion
###end title 36
###begin p 37
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRNP </italic>
###xml 149 154 149 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRNP </italic>
###xml 327 332 327 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRNP </italic>
PRNP 1368 polymorphism was not significantly associated with incidence of sporadic AD and VaD in Koreans. However, in the haplotype analysis among 3 PRNP polymorphisms, we observed a significant association between haplotype ht5 and VaD. Our report is the first association study of a polymorphism outside the coding region of PRNP with AD and VaD.
###end p 37
###begin title 38
Competing interests
###end title 38
###begin p 39
The authors declare that they have no competing interests.
###end p 39
###begin title 40
Authors' contributions
###end title 40
###begin p 41
BHJ and YSK designed the study. BHJ, KHL, and YJL performed the genotyping. BHJ, YJK, EKC, YHK, YSC, and YSK analyzed the data. BHJ, EKC, and YJK performed statistical analysis. BHJ, YJK, RIC, and YSK wrote the paper. All authors read and approved the final manuscript.
###end p 41
###begin title 42
Pre-publication history
###end title 42
###begin p 43
The pre-publication history for this paper can be accessed here:
###end p 43
###begin p 44

###end p 44
###begin title 45
Acknowledgements
###end title 45
###begin p 46
This work was supported by the Korea Research Foundation Grant funded by the Korean Government (MOEHRD) (KRF-2006-311-E00034).
###end p 46
###begin article-title 47
The genetic epidemiology of neurodegenerative disease
###end article-title 47
###begin article-title 48
Prion protein immunoreactivity in brain samples from an unselected autopsy population: findings in 200 consecutive cases
###end article-title 48
###begin article-title 49
Prion protein expression in senile plaques in Alzheimer's disease
###end article-title 49
###begin article-title 50
###xml 93 98 <span type="species:ncbi:9606">human</span>
Immunohistochemistry for the prion protein: comparison of different monoclonal antibodies in human prion disease subtypes
###end article-title 50
###begin article-title 51
Coexistence of Alzheimer-type neuropathology in Creutzfeldt-Jakob disease
###end article-title 51
###begin article-title 52
Prion disease genetics
###end article-title 52
###begin article-title 53
Genetic prion disease: the EUROCJD experience
###end article-title 53
###begin article-title 54
###xml 83 91 <span type="species:ncbi:9606">patients</span>
Codon 219 polymorphism of PRNP in healthy Caucasians and Creutzfeldt-Jakob disease patients
###end article-title 54
###begin article-title 55
Association of sporadic Creutzfeldt-Jakob disease with homozygous genotypes at PRNP codons 129 and 219 in the Korean population
###end article-title 55
###begin article-title 56
Homozygous prion protein genotype predisposes to sporadic Creutzfeldt-Jakob disease
###end article-title 56
###begin article-title 57
Codon 219 Lys allele of PRNP is not found in sporadic Creutzfeldt-Jakob disease
###end article-title 57
###begin article-title 58
PRNP Val129 homozygosity increases risk for early-onset Alzheimer's disease
###end article-title 58
###begin article-title 59
Prion protein gene M129 allele is a risk factor for Alzheimer's disease
###end article-title 59
###begin article-title 60
Polymorphisms within the prion (PrP) and prion-like protein (Doppel) genes in AD
###end article-title 60
###begin article-title 61
Prion protein codon 129 polymorphism and risk of Alzheimer disease
###end article-title 61
###begin article-title 62
Prion protein gene polymorphism and Alzheimer's disease: one modulatory trait of cognitive decline?
###end article-title 62
###begin article-title 63
Polymorphism at codon 129 of the prion protein gene is not associated with sporadic AD
###end article-title 63
###begin article-title 64
Is M129V of PRNP gene associated with Alzheimer's disease? A case-control study and a meta-analysis
###end article-title 64
###begin article-title 65
Absence of association between codon 129/219 polymorphisms of the prion protein gene and Alzheimer's disease in Japan
###end article-title 65
###begin article-title 66
Significant association of a M129V independent polymorphism in the 5' UTR of the PRNP gene with sporadic Creutzfeldt-Jakob disease in a large German case-control study
###end article-title 66
###begin article-title 67
Sporadic-but not variant-Creutzfeldt-Jakob disease is associated with polymorphisms upstream of PRNP exon 1
###end article-title 67
###begin article-title 68
Polymorphisms in the prion protein gene and in the doppel gene increase susceptibility for Creutzfeldt-Jakob disease
###end article-title 68
###begin article-title 69
PRNP 1368 polymorphism is not associated with sporadic Creutzfeldt-Jakob disease in the Korean population
###end article-title 69
###begin article-title 70
Prion protein (PRNP) genotypes in frontotemporal lobar degeneration syndromes
###end article-title 70
###begin article-title 71
###xml 128 133 <span type="species:ncbi:9606">Human</span>
Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease
###end article-title 71
###begin article-title 72
Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop
###end article-title 72
###begin article-title 73
A new statistical method for haplotype reconstruction from population data
###end article-title 73
###begin article-title 74
Polymorphisms of the prion protein gene (PRNP) in a Korean population
###end article-title 74
###begin article-title 75
Polymorphisms at codons 129 and 219 of the prion protein gene (PRNP) are not associated with sporadic Alzheimer's disease in the Korean population
###end article-title 75
###begin article-title 76
Absence of association between codon 129 and 219 polymorphisms of the prion protein gene and vascular dementia
###end article-title 76
###begin article-title 77
###xml 88 94 <span type="species:ncbi:9913">cattle</span>
Genotype distribution of the prion protein gene (PRNP) promoter polymorphisms in Korean cattle
###end article-title 77
###begin article-title 78
Functional relevance of DNA polymorphisms within the promoter region of the prion protein gene and their association to BSE infection
###end article-title 78
###begin article-title 79
###xml 58 68 <span type="species:ncbi:9913">Bos taurus</span>
###xml 92 98 <span type="species:ncbi:9913">cattle</span>
Polymorphisms of the prion protein gene (PRNP) in Hanwoo (Bos taurus coreanae) and Holstein cattle
###end article-title 79
###begin article-title 80
###xml 0 6 <span type="species:ncbi:9913">Bovine</span>
###xml 123 129 <span type="species:ncbi:9913">bovine</span>
Bovine prion protein gene (PRNP) promoter polymorphisms modulate PRNP expression and may be responsible for differences in bovine spongiform encephalopathy susceptibility
###end article-title 80
###begin article-title 81
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice devoid of PrP are resistant to scrapie
###end article-title 81
###begin article-title 82
###xml 129 133 <span type="species:ncbi:10090">mice</span>
Paradoxical shortening of scrapie incubation times by expression of prion protein transgenes derived from long incubation period mice
###end article-title 82
###begin article-title 83
PRNP contains both intronic and upstream regulatory regions that may influence susceptibility to Creutzfeldt-Jakob Disease
###end article-title 83
###begin article-title 84
Regulatory sequences of the PRNP gene influence susceptibility to sporadic Creutzfeldt-Jakob disease
###end article-title 84

